We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+49.04%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$18.8B
AUM Growth
+$4.11B
Cap. Flow
-$554M
Cap. Flow %
-2.95%
Top 10 Hldgs %
85.02%
Holding
117
New
8
Increased
21
Reduced
10
Closed
18

Top Buys

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$227M
2
DBVT
DBV Technologies
DBVT
+$72.8M
3
KOD icon
Kodiak Sciences
KOD
+$69.2M
4
KRRO icon
Korro Bio
KRRO
+$19.2M
5
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$15.7M

Top Sells

Rank Stock Value
1
GHDX
Genomic Health, Inc.
GHDX
+$627M
2
AMRN
Amarin Corp
AMRN
+$134M
3
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$72.9M
4
NGNE icon
Neurogene
NGNE
+$39.4M
5
CBAY
Cymabay Therapeutics
CBAY
+$29.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.66%
2 Financials 0.01%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MIST icon
101
Milestone Pharmaceuticals
MIST
$131M
– –
-266,667
Closed -$4.97M
AIXC
102
AIxCrypto Holdings Inc
AIXC
$22.7M
– –
-22
Closed -$87K
XBIT icon
103
XBiotech
XBIT
$69.5M
– –
-521,327
Closed -$5.45M
CBAY
104
DELISTED
Cymabay Therapeutics
CBAY
– –
-5,707,411
Closed -$29.2M
ACOR
105
DELISTED
Acorda Therapeutics
ACOR
– –
-18,605
Closed -$6.41M
SRRA
106
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
– –
-50,000
Closed -$781K
XLRN
107
DELISTED
Acceleron Pharma
XLRN
– –
-83,900
Closed -$3.31M
FTSV
108
DELISTED
Forty Seven, Inc. Common Stock
FTSV
– –
-250,000
Closed -$1.6M
FOMX
109
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
– –
-498,189
Closed -$1.51M
DERM
110
DELISTED
Dermira, Inc.
DERM
– –
-906,943
Closed -$5.79M
ACHN
111
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-1,095,359
Closed -$3.94M
ONCE
112
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
– –
-751,927
Closed -$72.9M
DOVA
113
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
– –
-102,205
Closed -$2.86M
GHDX
114
DELISTED
Genomic Health, Inc.
GHDX
– –
-9,244,665
Closed -$627M
LJPC
115
DELISTED
La Jolla Pharmaceutical Company
LJPC
– –
-1,559,231
Closed -$13.7M
1 2 3 4
5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q4 2019 Portfolio in Review

As of Q4 2019, Julian Baker held 117 positions worth $18.8B, up 28% from $14.7B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Julian Baker's Q4 2019 filing shows 8 new, 21 increased, 10 reduced and 18 closed positions. Its largest new stake was Exact Sciences: 2,585,791 shares worth $239M. The largest sale was Genomic Health, Inc., an estimated $627M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials and Technology.

  • Julian Baker's largest Q4 2019 buy was Exact Sciences: 2,585,791 shares worth $239M.
  • Julian Baker added most to DBV Technologies in Q4 2019, an estimated $72.8M increase.
  • Julian Baker's biggest Q4 2019 reduction was Amarin Corp, cutting an estimated $134M.
  • Julian Baker fully exited Genomic Health, Inc. in Q4 2019, selling an estimated $627M.
  • Julian Baker's ten largest holdings make up 85% of its $18.8B portfolio in Q4 2019.
  • Julian Baker opened 8 new positions and closed 18 in Q4 2019.
  • Julian Baker's portfolio value rose 28% quarter-over-quarter to $18.8B.

Based on Baker Bros. Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.